The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: A survey of practice patterns and pregnancy outcomes

Journal of Rheumatology

Volumn 30, Issue 2, 2003, Pages 241-246

  Chakravarty, Eliza F ^a,b   Sanchez Yamamoto, Deanna ^a,b   Bush, Thomas M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Congenital malformations; Etanercept; Leflunomide infliximab; Methotrexate; Pregnancy; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BIRTH CONTROL; CLINICAL PRACTICE; CONGENITAL MALFORMATION; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG USE; FEMALE; FETUS RISK; HUMAN; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NORMAL HUMAN; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK FACTOR; TERATOGENICITY; TREATMENT CONTRAINDICATION; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS;

EID: 0037309462     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Reich EW, Cox RP, Becker MH, Genieser NB, McCarthy JG, Converse JM. Recognition in adult patients of malformations induced by folic-acid antagonists. Birth Defects 1978; 14:139-60.
2. Milunsky A, Graef JW, Gaynor MF. Methotrexate-induced congenital malformations. J Pediatr 1968;72:790-5.
3. Powell HR, Ekert H. Methotrexate-induced congenital malformations. Med J Aust 1971;2:1076-7.
4. Kozlowski RD, Steïnbrunner JV, MacKenzie AH, Clough JD, Wilkie WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92.
5. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47:533-9.
6. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
7. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-3.
8. Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 1999;60:10-2.
9. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000;27:1872-5.
10. Leflunomide package insert. Kansas City, MO: Aventis Pharmaceuticals Inc; 2000.
11. Enbrel package insert. Seattle, WA: Immunex Corporation; 2001.
12. Infliximab package insert. Malvern, PA: Centocor, Inc.; 2000.
13. Antoni CE, Furst D, Manger B, et al. Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S153.
14. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000;160:610-9.
15. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of RA, 2002 update. Arthritis Rheum 2002;46:328-46.
16. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995;333:537-40.
17. Schuna AA. Update on treatment of rheumatoid arthritis. J Am Pharm Assoc 1998;38:728-35.
18. California Birth Defects Monitoring Program. Birth defects in California: 1983-1990. Emeryville, CA: California Birth Defects Monitoring Program; 1994.
19. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58:1137-64.
20. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyramiding synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12.
21. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
22. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997;50:1129-36.
23. Kellerman SE, Herold J. Physician response to surveys. Am J Prev Med 2001;20:61-7.
24. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res 2001;35:1347-55.
25. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-9.
26. Centers for Disease Control. Unintended pregnancy - New York, 1988-1989. MMWR 1991;40:723-5.
27. Mishell DR. Prevention of unplanned pregnancy in U.S. women. J Reprod Med 2000;45:867-71.
28. Oakley D, Potter L, de Leon-Wong E, Visness C. Oral contraceptive use and protective behavior after missed pills. Fam Plann Perspect 1997:29:277-9.